|本期目录/Table of Contents|

[1]李奕鑫,林平冬,徐 涛,等.益气清肝汤联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床研究[J].医学研究与战创伤救治(原医学研究生学报),2012,14(01):42-44.
　LI Yi-xin,LIN Ping-dong,XU Tao,et al.Clinical therapeutic effect of Yi Qi Qing Gan Tang combined with entecavir on hepatic fibrosis of chronic hepatitis B[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2012,14(01):42-44.
点击复制

益气清肝汤联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床研究()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第14卷
期数:
2012年01期
页码:
42-44
栏目:
出版日期:
2012-01-20

文章信息/Info

Title:
Clinical therapeutic effect of Yi Qi Qing Gan Tang combined with entecavir on hepatic fibrosis of chronic hepatitis B
文章编号:
1672-271X(2012)01-0042-03
作者:
李奕鑫; 林平冬; 徐 涛; 陈育霞; 刘理冠; 李勇飞
362000 福建泉州，解放军180医院南京军区临床肝病研究中心
Author(s):
LI Yi-xin; LIN Ping-dong; XU Tao; CHEN Yu-xia; LIU Li-guan; LI Yong-fei.
Live Center of Nanjing Military Command,180 Hospital of PLA,Quanzhou,Fujian 362000,China
关键词:
乙型肝炎; 肝纤维化; 益气清肝汤; 恩替卡韦
Keywords:
HBV;  hepatic fibrosis;  Yi Qi Qing Gan Tang;  entecavir
分类号:
R512.62
DOI:
-
文献标志码:
A
摘要:
目的 观察益气清肝汤联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床疗效。方法 慢性乙型肝炎肝纤维化76例随机分为对照组和观察组，观察组采用益气清肝汤联合恩替卡韦进行治疗，对照组采用恩替卡韦治疗。观察治疗后两组血清肝纤维化指标和主要临床症状的变化情况。结果 两组患者肝纤维化指标均较治疗前明显下降(P<0.05)；治疗结束时观察组纤维化指标变化值与对照组比较差异有统计学意义(P<0.05)。两组患者经治疗后血清 HBV-DNA 水平均明显下降，但转阴率无明显差异(P>0.05)；两组主要临床症状均有明显改善，其中观察组在纳差和皮肤巩膜黄染消退方面显著优于对照组(P<0.05)。结论 益气清肝汤联合恩替卡韦治疗慢性乙型肝炎肝纤维化临床疗效较单独使用恩替卡韦更好。
Abstract:
Objective To evaluate the clinical therapeutic effect of Yi Qi Qing Gan Tang combined with entecavir on hepatic fibrosis of chronic hepatitis B.Methods 76 patients with hepatic fibrosis of chronic hepatitis B were randomly divided into the group treated entecavir (0.5 mg/d) combined with Yi Qi Qing Gan Tang (n=39), and the control group treated entecavir (n=37, 0.5 mg/d).Serum fibrosis markers and major changes in clinical symptoms were observed after 48 weeks.Results The serum HBV-DNA levels and liver fibrosis of patients in two groups were significantly decreased after treating (P<0.05).No significant difference of the serum HBV-DNA levels was found between two groups (P>0.05).The clinical symptoms were significantly improved.The anorexia and yellowish discoloration of skin in treatment group were significantly better than that in the control group (P<0.05).Conclusion Yi Qi Qing Gan Tang combined with Entecavir has a good effect on liver cirrhosis of HBV.

参考文献/References:

[1]中国中西医结合学会肝病专业委员会.肝纤维化中西医结合诊疗指南[J].中西医结合肝病杂志,2006,16(5):316-320.
[2]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:143-151.
[3]叶 放,薛博瑜,周 珉,等.论湿热瘀毒与肝纤维化[J].南京中医药大学学报,2005,21(6):346-349.
[4]赵育芳,孙国凌,奚胜艳,等.中医抗肝纤维化组方规律的文献研究[J].中医杂志,2011,52(14):1233-1235,1245.
[5]中华肝脏病学会肝纤维化学组.肝纤维化诊断及疗效评估共识[J].中华肝脏病杂志,2002,10(5):327-328.
[6] Tenney DJ,Rose RE,Baldick CJ,et al.Long-term monitoring sh-ows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy[J].Hepatology，2009，49(5):1503-1514.
[7]潘雪飞,杜 斌,范 群,等.综合分析药物性肝损伤4076例[J].东南国防医药，2009,11(6):505-507.
[8]李 治,苏 华,冷 静.国内外药物性肝损害状况分析[J].东南国防医药，2007,9(6):476-480.
[9]彭晓明，王 煜，刘 娅.恩替卡韦在慢性乙型重型肝炎中的应用[J].包头医学，2011,35(3):129-131.
[10]王朝晖.恩替卡韦治疗慢性乙型重型肝炎近期疗效观察[J].中国医药指南，2011,9(26):283-285.
[11]李 青.国产恩替卡韦治疗初治HBeAg阳性慢乙肝患者24周的早期临床疗效观察[J].中国医疗前沿，2011,6(17):20-21.
[12]徐鹤翔，余亚新，张明侠，等.替比夫定和恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者早期疗效分析[J].实用肝脏病杂志，2011,14(4):265-267.

相似文献/References:

[1]朱先存,张纯林,左鲁生,等.声触诊组织量化技术诊断早期肝硬化的临床价值[J].医学研究与战创伤救治(原医学研究生学报),2012,14(06):511.
　ZHU Xian-cun,ZHANG Chun-lin,ZUO Lu-sheng,et al.The clinic value of virtual touch tissue quantification technique in diagnosis of early liver cirrhosis[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2012,14(01):511.
[2]周晓辉,闫 冰,潘士勇,等.软肝灵对肝纤维化小鼠肝组织病理学及抗脂质过氧化作用的影响[J].医学研究与战创伤救治(原医学研究生学报),2012,14(04):297.
　ZHOU Xiao-hui,YAN Bing,PAN Shi-yong,et al.Effects of Ruan gan ling on liver fibrosis pathology and inhibit peroxidation induced by carbon tetrachloride in mice[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2012,14(01):297.
[3]冯青青,樊拖迎,李春安,等.乙型肝炎后肝硬化患者胆结石形成的机制探讨[J].医学研究与战创伤救治(原医学研究生学报),2011,13(03):217.
　FENG Qing-qing,FAN Tuo-ying,LI Chun-an,et al.Mechanism of gallstone formation in patients with cirrhosis after hepatitis B[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2011,13(01):217.
[4]梅 琪,虞 梅,张 菁,等.ARFI技术与血清铁、铁蛋白和肝纤维化四项检测在肝纤维化及肝硬化诊断中的相关性[J].医学研究与战创伤救治(原医学研究生学报),2014,16(03):241.[doi:10.3969/j.issn.1672-271X.2014.03.005]
　MEI Qi,YU Mei,ZHANG Jing,et al.Analysis of the correlation between ARFI and four indexes of serum liver fibrosis in the diagnosis of liver diseases[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2014,16(01):241.[doi:10.3969/j.issn.1672-271X.2014.03.005]
[5]王 琳,蔡丽萍,孙燕双.声触诊组织量化技术在预测肝纤维化患者门静脉高压发生风险中的价值[J].医学研究与战创伤救治(原医学研究生学报),2015,17(06):610.[doi:10.3969/j.issn.1672-271X.2015.06.015]
　WANG Lin,CAI Li-ping,SUN Yan-shuang..Value ofvirtual touch tissues quantification technique in predicting the occurrence risk of portal hypertension of patients suffering from hepatic fibrosis[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(01):610.[doi:10.3969/j.issn.1672-271X.2015.06.015]
[6]吴鸿雁,黄睿,熊亚莉,等.不同病因慢性肝病患者肝组织中IL-10的表达及意义[J].医学研究与战创伤救治(原医学研究生学报),2016,18(02):122.[doi:10.3969/j.issn.1672-271X.2016.02.004]
　WU Hong-yan,HUANG Rui,XIONG Ya-li,et al.Expression of interleukin-10 in the liver tissues of patients with chronic liver diseases of different etiologies[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(01):122.[doi:10.3969/j.issn.1672-271X.2016.02.004]
[7]张骏飞,郭远,陈从新,等.替比夫定治疗慢加亚急性乙型肝炎肝衰竭的疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2016,18(02):131.[doi:10.3969/j.issn.1672-271X.2016.02.007]
　ZHANG Jun-fei,GUO Yuan,CHEN Cong-xin,et al.A study on the treatment effect of telbivudine on hepatitis B patients with acute on chronic liver failure[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(01):131.[doi:10.3969/j.issn.1672-271X.2016.02.007]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2012-01-20